Ebola Vaccine: How Far Are We?

Overview

Journal J Clin Diagn Res

Specialty General Medicine

Date 2017 Jun 30

PMID 28658761

Citations 3

Authors

Rajani Sharma

Ketki Jangid

Anuradha

Affiliations

Soon will be listed here.

Abstract

Ebola viruses have been identified as an emerging threat as it causes severe haemorrhagic fever in human with mortality rates ranging from 50 to 90%. In addition to being a global health concern, the virus also is considered a potential biological threat agent. As for now, no licensed vaccine is available for pre or post exposure treatment. Recent epidemic of this disease in South Africa has led to concern towards development of an effective vaccine on a priority basis. This review is an attempt to look upon current progress in the development of Ebola virus vaccines and highlights strategies that have the greatest potential for commercial development.

Citing Articles

Structural and Functional Aspects of Ebola Virus Proteins.

Jain S, Martynova E, Rizvanov A, Khaiboullina S, Baranwal M Pathogens. 2021; 10(10).

PMID: 34684279 PMC: 8538763. DOI: 10.3390/pathogens10101330.

Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach.

Olukitibi T, Ao Z, Mahmoudi M, Kobinger G, Yao X Microorganisms. 2019; 7(10).

PMID: 31569539 PMC: 6843631. DOI: 10.3390/microorganisms7100402.

The molecular tweezer CLR01 inhibits Ebola and Zika virus infection.

Rocker A, Muller J, Dietzel E, Harms M, Kruger F, Heid C Antiviral Res. 2018; 152:26-35.

PMID: 29428508 PMC: 7113745. DOI: 10.1016/j.antiviral.2018.02.003.

References

Geisbert T, Feldmann H . Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011; 204 Suppl 3:S1075-81. PMC: 3218670. DOI: 10.1093/infdis/jir349. View

Peters C, Khan A . Filovirus diseases. Curr Top Microbiol Immunol. 1999; 235:85-95. DOI: 10.1007/978-3-642-59949-1_6. View

Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R . Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol. 2004; 78(10):5458-65. PMC: 400370. DOI: 10.1128/jvi.78.10.5458-5465.2004. View

Perez S, Kallinteris N, Bisias S, Tzonis P, Georgakopoulou K, Varla-Leftherioti M . Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res. 2010; 16(13):3495-506. DOI: 10.1158/1078-0432.CCR-10-0085. View

Bukreyev A, Skiadopoulos M, Murphy B, Collins P . Nonsegmented negative-strand viruses as vaccine vectors. J Virol. 2006; 80(21):10293-306. PMC: 1641758. DOI: 10.1128/JVI.00919-06. View

Fisher-Hoch S, Platt G, Neild G, Southee T, Baskerville A, Raymond R . Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola). J Infect Dis. 1985; 152(5):887-94. DOI: 10.1093/infdis/152.5.887. View

Sullivan N, Geisbert T, Geisbert J, Shedlock D, Xu L, Lamoreaux L . Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 2006; 3(6):e177. PMC: 1459482. DOI: 10.1371/journal.pmed.0030177. View

Robinson H, Pertmer T . DNA vaccines for viral infections: basic studies and applications. Adv Virus Res. 2000; 55:1-74. DOI: 10.1016/s0065-3527(00)55001-5. View

Mellquist-Riemenschneider J, Garrison A, Geisbert J, Saikh K, Heidebrink K, Jahrling P . Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for EBOLA virus in guinea pigs. Virus Res. 2003; 92(2):187-93. DOI: 10.1016/s0168-1702(02)00338-6. View

10.

Erskine C, Krco C, Hedin K, Borson N, Kalli K, Behrens M . MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. J Immunol. 2011; 187(1):316-24. PMC: 3119756. DOI: 10.4049/jimmunol.1100658. View

11.

Colebunders R, Borchert M . Ebola haemorrhagic fever--a review. J Infect. 2000; 40(1):16-20. DOI: 10.1053/jinf.1999.0603. View

12.

Kobinger G, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F . Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2005; 346(2):394-401. DOI: 10.1016/j.virol.2005.10.042. View

13.

Qiu X, Fernando L, Alimonti J, Melito P, Feldmann F, Dick D . Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One. 2009; 4(5):e5547. PMC: 2678264. DOI: 10.1371/journal.pone.0005547. View

14.

ELLIOTT L, Kiley M, McCormick J . Descriptive analysis of Ebola virus proteins. Virology. 1985; 147(1):169-76. DOI: 10.1016/0042-6822(85)90236-3. View

15.

Lupton H, LAMBERT R, Bumgardner D, Moe J, Eddy G . Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet. 1980; 2(8207):1294-5. DOI: 10.1016/s0140-6736(80)92352-1. View

16.

Kolesnikova L, Berghofer B, Bamberg S, Becker S . Multivesicular bodies as a platform for formation of the Marburg virus envelope. J Virol. 2004; 78(22):12277-87. PMC: 525088. DOI: 10.1128/JVI.78.22.12277-12287.2004. View

17.

Ignatyev G, Agafonov A, Streltsova M, Kashentseva E . Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. J Biotechnol. 1996; 44(1-3):111-8. DOI: 10.1016/0168-1656(95)00104-2. View

18.

Sullivan N, Sanchez A, Rollin P, Yang Z, Nabel G . Development of a preventive vaccine for Ebola virus infection in primates. Nature. 2000; 408(6812):605-9. DOI: 10.1038/35046108. View

19.

. Positive Phase II interim data on AE37 cancer vaccine released. Hum Vaccin Immunother. 2012; 8(2):152. DOI: 10.4161/hv.19658. View

20.

Warfield K, Olinger G, Deal E, Swenson D, Bailey M, Negley D . Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol. 2005; 175(2):1184-91. DOI: 10.4049/jimmunol.175.2.1184. View